visit the website If, at any time, you are interested in reverting to our default settings, please select Default Setting above. If you have any questions or encounter any issues in changing your default settings, please email firstname.lastname@example.org . Please confirm your selection: You have selected to change your default setting for the Quote Search. This will now be your default target page; unless you change your configuration again, or you delete your cookies.
ETF Outlook: Guggenheim S&P Equal Weight Health Care ETF (RYH) - NASDAQ.com
It also anticipates a net operating loss on a GAAP basis, but expects to be profitable on a non-GAAP basis for Q4. The Street's latest forecast was for a GAAP loss of $0.04 per share and a non-GAAP profit of $0.01 per share. For the full year, the company expects revenue to be in the range of $74 million to $75 million and expects to incur a net operating loss on both a GAAP and non-GAAP basis. Previously, the company forecast revenue for the year in the range of $70 million to $75 million. Analysts recently were looking for $72.2 million in revenue, a non-GAAP loss of $0.26 per share and a GAAP loss of $1.04. Energy Dow Jones U.S.
ETF Report: ETFs, Stocks Higher as Crude Oil Recovers; FOMC Meeting Minutes Still Ahead - NASDAQ.com
With the Health Care Sector likely to continue to outperform the broad market and the Biotech stocks regrouping, the RYH is an excellent way to participate in a renewed market advance. Biotech stocks are the most volatile component of the RYH but have very exciting new drugs in the pipelines. As such, they will provide a tailwind for the RYH which should push this ETF to new highs. Use any short-term dips to buy the RYH in anticipation of renewed strength in this strong sector in the weeks ahead. The Guggenheim S&P Equal Weight Health Care ETF (RYH) has 20 Bullish-rated Chaikin Power Gauge stocks vs. 4 with Bearish ratings, as indicated by the Chaikin Power Bar for the RYH below.
JPMorgan Chase (JPM) Stock Up Today After Launching New ETF - TheStreet
TheStreet Ratings Team has this to say about their recommendation: "We rate JPMORGAN CHASE & CO (JPM) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth, increase in stock price during the past year, impressive record of earnings per share growth and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow." Highlights from the analysis by TheStreet Ratings Team goes as follows: The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Commercial Banks industry. The net income increased by 1566.3% when compared to the same quarter one year prior, rising from -$380.00 million to $5,572.00 million.
Notable ETF Inflow Detected - XLB, LYB, PPG, APD - NASDAQ.com
(Symbol: PPG) is up about 1.9%, and Air Products & Chemicals, Inc. (Symbol: APD) is higher by about 1.8%. For a complete list of holdings, visit the XLB Holdings page The chart below shows the one year price performance of XLB, versus its 200 day moving average: Looking at the chart above, XLB's low point in its 52 week range is $42.78 per share, with $51.01 as the 52 week high point - that compares with a last trade of $48.43. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average . Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''.